ClinicalTrials.gg

Hepatitis C clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,744 studies for Hepatitis C across more than 10 countries. 98 are recruiting or about to start. 1,195 of them are mainly about Hepatitis C (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Hepatitis C, Chronic too: 2,376 studies, 102 open.

ClinicalTrials.gov finds 2,574 studies for Hepatitis C. How that becomes 1,744 here

This page counts the studies the registry files under Hepatitis C, and those it files under no condition that list Hepatitis Cthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,574Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −632Filed under a narrower condition, counted on its own pageHepatitis C, Chronic 589
  3. −23List Hepatitis C as a condition, but the registry did not file them under itMost often written as “Chronic Hepatitis C Virus Infection” (4), “Cirrhosis Due to Hepatitis C” (4), and “Hepatitis C Virus Chronic Infection” (3). The registry filed them under other conditions only, most often Fibrosis (5) and HIV Infections (4).
  4. −175Match it another way110 name it in the title, 8 in a keyword, and 57 by a synonym or other text the search reads.
  5. 1,744The count on this page22 of them list Hepatitis C in their own words; the registry filed them under no condition.

Status

Completed
1,230
Status unknown
191
Terminated
129
Withdrawn
73
Recruiting
56
Not yet recruiting
37

Phase

Phase 2
347
Phase 3
287
Phase 1
268
Phase 4
187
Early Phase 1
5

Where

United States
725
France
174
Canada
146
Germany
128
Puerto Rico
124
Spain
116

Who develops what

Add Hepatitis C to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 1 company, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
RibavirinEarlier onlyPhase 4 trial recorded
Evidence
  • NCT04155515 · Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. · Phase 3 · background · “Ribavirin” · registered Nov 2019
  • NCT03833362 · R-Pharm · Phase 3 · background · “Ribavirin” · registered Feb 2019
  • NCT02956629 · Merck & Co., Inc · Phase 2 · background · “Ribavirin” · registered Nov 2016
  • NCT02939989 · AbbVie · Phase 3 · background · “Ribavirin” · registered Oct 2016
  • NCT02723084 · AbbVie · Phase 3 · comparator · “ribavirin (RBV)” · registered Mar 2016
Hoffmann-La Roche19% of its industry studies00 studies
peginterferon alfa-2aEarlier only
Evidence
  • NCT03833362 · R-Pharm · Phase 3 · background · “Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b” · registered Feb 2019
  • NCT01889433 · Biocad · Phase 3 · comparator · “Pegasys” · registered Jun 2013
  • NCT01854697 · AbbVie · Phase 3 · comparator · “Pegylated Interferon alpha 2-a (PegIFN)” · registered Apr 2013
  • NCT01797848 · Bristol-Myers Squibb · Phase 3 · background · “Peginterferon alfa 2a” · registered Feb 2013
  • NCT01754974 · Bristol-Myers Squibb · Phase 3 · comparator · “Peginterferon alfa-2a” · registered Dec 2012
Hoffmann-La Roche67% of its industry studiesUS: pharmaand GmbH (FDA 2002)EU: pharmaand GmbH (EMA 2002)00 studies
peginterferon alfa-2bEarlier onlyPhase 4 trial recorded
Evidence
  • NCT03833362 · R-Pharm · Phase 3 · background · “Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b” · registered Feb 2019
  • NCT02103439 · Biocad · Phase 3 · comparator · “PegIntron” · registered Apr 2014
  • NCT01871662 · Rottapharm · Phase 3 · background · “Pegylated interferon alfa2b” · registered May 2013
  • NCT01740089 · Biocad · Phase 3 · comparator · “PegIntron” · registered Nov 2012
  • NCT01366638 · Johnson & Johnson · Phase 3 · background · “Peginterferon alfa-2b (pegIFN alfa-2b)” · registered Jun 2011
Merck & Co., Inc80% of its industry studies00 studies

6 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.Bemnifosbuvir-Ruzasvir · Atea Pharmaceuticals, Inc. · Phase 3 named, not the main aimNCT07037277 C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV — primary endpoint: Portion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at week 24 · 880 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hepatitis C studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Reverse transcriptase inhibitors 14 · Integrase inhibitors 10 · Calcineurin inhibitors 8 · SSRIs 7 · Statins 7

Coming up

28studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger. 10 (18%) take children under 18. 2 (4%) are for women only and 2 (4%) for men only; 26 (46%) take healthy volunteers.

Recruiting studies that take each age, of 56
AgeWomenMen
108 (14%)8 (14%)
1852 (93%)52 (93%)
3053 (95%)53 (95%)
4053 (95%)53 (95%)
5053 (95%)54 (96%)
6553 (95%)53 (95%)
7550 (89%)50 (89%)
8547 (84%)47 (84%)

Across all 1,744 studies, recruiting or not: 40% stop at 75 or younger and 24% at 65; 9% take children; 2% are for women only and 3% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hepatitis C studies take

Of 90 phase 3 interventional studies under Hepatitis C, half reached primary completion within 14 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 19 mo4–22 · 45 studies6 mo4–11 · 28 studies—
Phase 219 mo13–36 · 61 studies17 mo11–26 · 48 studies—
Phase 2/325 mo14–51 · 14 studies——
Phase 314 mo10–22 · 90 studies13 mo10–18 · 68 studies—
Phase 424 mo16–48 · 58 studies—24 mo17–49 · 56 studies
Interventional, no phase25 mo14–42 · 153 studies—26 mo15–42 · 150 studies
Observational33 mo18–57 · 138 studies26 mo18–56 · 36 studies36 mo16–63 · 102 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,744. Browse all 1,744 → or search them.